3-(((1R,3r,5S)-8-benzyl-8-azabicyclo[3.2.1]octan-3-yl)thio)benzamide | 1253405-20-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-(((1R,3r,5S)-8-benzyl-8-azabicyclo[3.2.1]octan-3-yl)thio)benzamide
• CAS: 1253405-20-7
• 化学式: C₂₁H₂₄N₂OS
• 分子量: 352.5
• InChiKey: HBVXHJWHKVRGLG-RUYXUALKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.07
• 重原子数：
  25.0
• 可旋转键数：
  5.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  46.33
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为产物：
  描述：

  3-(((1R,3r,5S)-8-benzyl-8-azabicyclo[3.2.1]octan-3-yl)thio)benzonitrile 在 水 作用下， 以 乙醇 为溶剂， 生成 3-(((1R,3r,5S)-8-benzyl-8-azabicyclo[3.2.1]octan-3-yl)thio)benzamide
  参考文献：
  名称：

  SAR development of a series of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as kappa opioid receptor antagonists. Part 2

  摘要：

  Further structure activity relationship studies on a previously reported 8-azabicyclo[3.2.1]octan-3-yloxy-benzamide series of potent and selective kappa opioid receptor antagonists is discussed. Modification of the pendant N-substitution to include a cyclohexylurea moiety produced analogs with greater in vitro opioid and hERG selectivity such as 12 (kappa IC50 = 172 nM, mu:kappa ratio = 93, delta:kappa ratio = >174, hERG IC50 = >33 mu M). Changes to the linker conformation and identity as well as to the benzamide ring moiety were also investigated. (c) 2010 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2010.07.112

文献信息

• SAR development of a series of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as kappa opioid receptor antagonists. Part 2
  作者：Todd A. Brugel、Reed W. Smith、Michael Balestra、Christopher Becker、Thalia Daniels、Gerard M. Koether、Scott R. Throner、Laura M. Panko、Dean G. Brown、Ruifeng Liu、John Gordon、Matthew F. Peters

  DOI：10.1016/j.bmcl.2010.07.112

  日期：2010.9

  Further structure activity relationship studies on a previously reported 8-azabicyclo[3.2.1]octan-3-yloxy-benzamide series of potent and selective kappa opioid receptor antagonists is discussed. Modification of the pendant N-substitution to include a cyclohexylurea moiety produced analogs with greater in vitro opioid and hERG selectivity such as 12 (kappa IC50 = 172 nM, mu:kappa ratio = 93, delta:kappa ratio = >174, hERG IC50 = >33 mu M). Changes to the linker conformation and identity as well as to the benzamide ring moiety were also investigated. (c) 2010 Published by Elsevier Ltd.